Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Intangibles (2019 - 2025)

Historic Intangibles for Legend Biotech (LEGN) over the last 7 years, with Q2 2025 value amounting to $2.1 million.

  • Legend Biotech's Intangibles fell 2290.76% to $2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.1 million, marking a year-over-year decrease of 2290.76%. This contributed to the annual value of $2.2 million for FY2024, which is 4681.11% down from last year.
  • Legend Biotech's Intangibles amounted to $2.1 million in Q2 2025, which was down 2290.76% from $2.1 million recorded in Q1 2025.
  • In the past 5 years, Legend Biotech's Intangibles registered a high of $6.4 million during Q4 2021, and its lowest value of $4081.0 during Q1 2021.
  • Moreover, its 5-year median value for Intangibles was $2.6 million (2024), whereas its average is $3.0 million.
  • Its Intangibles has fluctuated over the past 5 years, first surged by 52120518.23% in 2021, then tumbled by 4932.48% in 2023.
  • Legend Biotech's Intangibles (Quarter) stood at $6.4 million in 2021, then plummeted by 46.75% to $3.4 million in 2022, then grew by 19.13% to $4.1 million in 2023, then plummeted by 46.81% to $2.2 million in 2024, then fell by 1.06% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q2 2025, $2.1 million for Q1 2025, and $2.2 million during Q4 2024.